Skip to main
TVTX
TVTX logo

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has demonstrated effective commercial execution, with the easing of REMS requirements expected to enhance prescriber adoption of its product, FILSPARI. The recent positive topline results from a Phase 3 bridging study in Japanese patients further solidify sparsentan's potential as a foundational therapy for IgA nephropathy, a rare kidney disorder. These developments have contributed to an accelerating sales trajectory and positive market sentiment surrounding the company’s stock.

Bears say

The negative outlook on Travere Therapeutics's stock is primarily driven by the potential for failed or inconclusive clinical trials, which poses a significant risk to the development of its lead candidate, sparsentan, for rare kidney disorders. Additionally, the company may face challenges in securing adequate funding to support its drug development pipeline, further exacerbating uncertainties surrounding its future financial stability. Recent changes within the FDA, including leadership shifts and evolving review practices, have created an environment of heightened scrutiny and investor apprehension in the biotech sector.

Travere Therapeutics (TVTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 13 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.